Asciminib (CML, first- and second-line treatment) – Second addendum to Project A25-150

Report documents

1. Addendum

   Asciminib (CML, first- and second-line treatment) – Second addendum to Project A25-150

   published on

   21.05.2026

   Document type

   PDF document, 296 kB, DE, not accessible

   DOI-Link

   https://doi.org/10.60584/G26-09

   Download file : Addendum (PDF document, 296 kB, DE, not accessible)

Additional information

Project details

Project no.

G26-09

Commission

Commission awarded on 08.04.2026 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Health Economics

Topic

Cancer

Note

If, in the course of the discussions on a commission of the GBA, a need for further revision arises, IQWiG submits an addendum. The GBA decides on the number of patients in the SHI target population.

DOI

https://doi.org/10.60584/G26-09

Connected Projects

1. Dossier assessment

   Asciminib (CML, first- and second-line treatment) – Benefit assessment according to §35a Social Code Book V

   Project no.

   A25-150

   Last updated

   21.05.2026

   Status: Commission completed